Objective: To determine the impact of mitral insufficiency on survival after reoperative coronary artery bypass grafting (CABG) in ischemic cardiomyopathy patients. Methods: We retrospectively studied 891 (Initial 708, Redo 183) consecutive CABG patients (1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002) with ejection fraction (EF) 35% or less. Patient characteristics: mean ageZ67.0G10.5 yrs, menZ77.1%, EFZ26.4G7.4%, mean CCSZ3.47G0.73, mean NYHAZ3.50G0.68. There were 180 (Initial 141, Redo 39) patients with 3/4Cmitral regurgitation (MR). Late survival statistics of cohorts were compiled using National Death Index. Results: At a mean follow-up period of 3 years, reoperative CABG with MR (Redo/MRC) survival was 41.7G9.2% (nZ39), which was worse than reoperative CABG without MR (Redo/MRK) survival of 71.8G4.1% (nZ144, PZ0.0003), initial CABG with MR (Initial/MRC) survival of 68.5G4.2% (nZ141, PZ0.014) and initial CABG without MR (Initial/MRK) survival of 76.2G2.0% (nZ567, P!0.0001). By multivariate analysis, congestive heart failure (PZ0.029), 3/4CMR (PZ0.044) were independent predictors of Redo late mortality. In contrast, renal failure on dialysis, stroke, no angina, age O65 yrs, absence of hypercholesterolemia, EF!26% but not 3/4CMR were independent predictors of Initial late mortality. In subset analysis, adverse impact of 3/4CMR on late survival was greatest in Redo with EF!26%. The 3-and 5-yr late survival were only 44.4 and 26.8% (PZ0.041). Concomitant mitral valve repair (MVrep) was performed in 100 (Initial 75, Redo 25) patients. MVrep in Initial/MRCpatients achieved similar late survival as Initial/MRK patients. MVrep did not produce the same late survival benefit in Redo/MRC patients. Conclusions: (1) Mitral insufficiency has a greater survival impact on redo than initial CABG patients with ischemic cardiomyopathy. (2) Mitral insufficiency and congestive heart failure are the primary independent predictors of late survival following redo CABG. (3) Mitral repair has less neutralizing effect on late survival in redo than initial CABG patients. q
Introduction
Mitral insufficiency is associated with poor survival in ischemic cardiomyopathy patients who are treated medically [1] or revascularized by PTCA or CABG [1, 2] . With enhanced myocardial protection, better understanding of ischemic mitral insufficiency and evolution of mitral valve repair and replacement techniques, the operative mortality of combined CABG and mitral-valve surgery has dramatically improved from 20-33% [3, 4] to 10-12% in recent series [5, 6] .
Nevertheless, the risk of surgical treatment in patients with severe left ventricular dysfunction and mitral insufficiency is still extremely high [3, 7] , and is further escalated in patients with prior CABG. In these patients, reoperation is fraught with potential hazards. Moreover, the amount of reversible myocardial disease is often uncertain, thus making surgical outcome unpredictable.
Although the risks of coronary reoperation in ischemic cardiomyopathy patients have been reported [8] [9] [10] , until now, the additional impact of mitral insufficiency has not been well defined. It also has not been clear how mitral insufficiency affects the late survival of patients undergoing redo CABG. Does mitral insufficiency in fact produce the same effect, in terms of operative risks and late survival, on the redo CABG patients as it does on the initial CABG patients? And is it legitimate to extrapolate from initial CABG patients with mitral insufficiency the criteria and guidelines to treat redo CABG patients with mitral insufficiency? To further our understanding of these patients, we retrospectively reviewed our 10-year operative experience in ischemic cardiomyopathy patients. Our goal was to determine the impact of mitral insufficiency on surgical risk and subsequent survival of redo CABG patients with severe left ventricular dysfunction. We also compare the effect of mitral insufficiency on survival of redo CABG patients versus initial CABG patients. The present study is in fact the first study that examines the impact of MR in ischemic cardiomyopathy patients undergoing redo CABG.
Materials and methods

Study group
From July 1993 to April 2002, 891 consecutive patients with ischemic cardiomyopathy, defined as having ejection fraction (EF) of 35% or less on angiography or echocardiography, underwent CABG at Loma Linda University Medical Center, Loma Linda, California, USA. Our institution's prospective cardiac surgery registry was used to identify these patients and obtain comprehensive perioperative information. Patients with prior mitral valve operation were excluded from the present retrospective study.
Of the 891 CAGB patients, 708 were initial CABG patients (Initial) and 183 reoperative CABG patients (Redo). Significant mitral regurgitation (MR), defined as grade 3 or 4 on echocardiography, was present in 180 patients. Since the main objective of the present study was to determine the impact of MR on reoperative coronary surgery, the study cohort was subdivided into four groups (Table 1) 
Patient variables
Using our prospective cardiac surgery registry, we analyzed 21 preoperative and 6 operative variables (Table 1) . Mortality was the outcome variable of the present study (Table 1) . Hospital mortality was defined as death from any cause within 1 month of operative date, or death at any time during total hospitalization. Subsequent death during follow-up defined late mortality, which was obtained from the National Death Index or most recent outpatient records and communications. Eleven surviving patients from foreign countries were excluded from follow-up due to anticipated difficulties in obtaining accurate information. Causes of mortality were not identified in the present study.
Surgical technique
Our approach to CABG operation has been previously described [11, 12] . We routinely used blood cardioplegia with retrograde coronary sinus delivery. Because of severe left ventricular dysfunction, we also incorporated into the myocardial protection scheme the delivery of continuous warm blood cardioplegia during a portion of, or the entire aortic cross-clamp period in, many patients. The precise delivery protocols varied according to surgeon and case. In recent years, more beating heart CABG operations were performed. Consequently, 80 patients (9.0%) had no cardioplegic arrest: off-pump in 59 patients and no aortic cross-clamping in 21 patients.
The mean cardiopulmonary bypass time was 130G 54 min (28-468 min), and the mean duration of aortic crossclamping was 82G34 min (0-230 min). On average, 2.48G 1.28 bypass grafts (1-6 grafts) per patient were performed and at least one arterial graft was used in 655 patients (73.5%).
Our approach to mitral insufficiency has evolved over time. Proportionally more mitral valves were repaired during the latter half of the study period. Posterior mitral annuloplasty was the principal repair technique. Over time, more Cosgrove-Edwards annuloplasty bands were implanted in preference to pericardial strips or other annuloplasty rings. Additional repair techniques (commissuroplasty, edge-to-edge leaflet approximation, and sliding posterior leaflet) were also more frequently utilized in recent years.
Statistical analysis
Data are summarized by frequencies and percentages for the discrete variables, and means and standard deviations for the continuous variables. Univariate analyses were performed by c 2 or Fisher exact tests for the discrete variables and Student's t-tests for the continuous variables.
Late survival statistic was obtained using the KaplanMeier method. Univariate analyses using the log-rank tests were used to access the individual relationship of each variable to survival. Variables that are at least marginally associated with survival on univariate analyses (P!0.15) were used to develop multivariate Cox proportional hazard models. Variables that were independently associated (P!0.05) with survival were then determined using stepwise regression methods.
Results
This cohort of 891 patients had the following characteristics: mean ageZ67.0G10.5 years, menZ77.1%, EFZ26.4G7.4%, mean CCS scoreZ3.47G0.73, mean NYHA scoreZ3.50G0.68. There were 180 (Initial 141, Redo 39) patients with 3/4CMR. There were only slight differences in the preoperative non-cardiac risk factors among the four groups. Of interest was the slight preponderance of diabetes mellitus in Initial patients and hypercholesterolemia in Redo patients. Renal insufficiency/failure was more prevalent in MR patients in both Initial and Redo patients. None of the non-cardiac comorbidities were significantly different between Redo/MRC and the other three groups.
MR patients had greater cardiac risk factors. Both Redo/ MRC and Initial/MRC had more heart failure than angina symptoms. Both had lower mean EF and more patients were on inotropic support preoperatively. The only difference between Redo/MRC and Initial/MRC was the higher incidence of left main coronary artery disease in Redo patients.
Operative characteristics (Table 1)
Of the 180 patients with 3/4CMR, 126 (70%) had MV repair or replacement. Concomitant cardiac operation therefore occurred with much greater frequency in Redo/MRC and Initial/MRC patients and were associated with much longer cardiopulmonary bypass and aortic crossclamped times. More than one-third of Initial/MRC patients had CABG alone, and was mostly operated on earlier in the study. Not surprisingly, Redo/MRC patients had the longest and the most complicated operations. Although Redo/MRC had longer cardiopulmonary bypass time when compared to Initial/MRC, the two groups had almost identical cross-clamped time.
Urgent patients were most common in Initial/MRK, Initial/MRC and Redo/MRK groups while Redo/MRC had the largest proportion of elective patients. As expected, intra-aortic balloon pumps were least utilized in Initial/ MRK patients.
Survival outcome (Table 1)
With a mean follow-up period of 3.0 years, the overall survival ( Fig. 1) of Redo/MRC (nZ39) was 41.7G9.2%, which was significantly worse than Redo/MRK (nZ144) of 71.8G4.1% (PZ0.0003, Initial/MRC (nZ141) of 68.5G 4.2% (PZ0.014) and Initial/MRK (nZ567) of 76.2G2.0% (P!0.0001).
In-hospital mortality was significantly higher in both Redo/MRC and Initial/MRC patients when compared to their respective subsets without mitral insufficiency. Late mortality, however, was significantly higher only in the Redo/MRC and not in the Initial/MRC patients. The lower overall actuarial survival in Initial/MRC patient was only due to the higher in-hospital mortality (Fig. 2) .
Late survivals of Initial/MRC and Initial/MRK were virtually identical. In contrast, both in-hospital mortality and late mortality contributed to the worst overall survival in Redo/MRC patients (Fig. 2) .
Late survival analysis
By univariate analysis (Table 2) , the only non-cardiac variable associated with decreased Redo late survival was chronic obstructive pulmonary disease. In contrast, older age, no hypercholesterolemia, chronic renal insufficiency, dialysis, stroke, chronic obstructive pulmonary disease, peripheral vascular disease were associated with decreased Initial late survival. Diabetes mellitus was not associated with decreased late survival in either group.
Congestive heart failure was the most significant cardiac risk factor in both Redo and Initial patients. Shock was associated with decreased Initial late survival while use of inotropes in Redo late survival. Absence of angina was associated with decreased late survival in Initial but not Redo patients. The most intriguing differences in cardiac risk factor between Redo and Initial patients were related to mitral insufficiency and ejection fraction. While 3/4CMR (Table 3 ). In this model, the clinical risk factors in Redo patients were all related to heart failure. In contrast, absence of angina but not necessarily heart failure was the important risk factor in Initial patients. There were no non-cardiac risk factors in Redo patients while older age, dialysis, stroke and no hypercholesterolemia were non-cardiac risk factors in Initial patients.
In the analysis of operative variables, elective Redo patients had similar poorer late survival as emergent Redo patients. This observation may be related to relatively greater proportion of Redo patients with 3/4CMR. While concomitant operation was associated with worse late survival in both Redo and Initial patients, concomitant mitral valve operation was a significant risk factor only in Redo and not Initial patients. Increased cardiopulmonary bypass time did not impact Redo late survival and only marginally worsen Initial late survival. Interestingly, longer aortic cross-clamped time was associated with improved late survival in Redo patients and no impact in Initial patients. In the multivariable model, operative risk factor in Initial patients was concomitant operation and in Redo patients shorter aortic cross-clamped time.
Concomitant mitral operation
Concomitant MV repair and MV replacement were performed in 100 (Initial 75, Redo 25) patients, and 26 (Initial 18, Redo 8) patients, respectively. In Initial/MRC patients, MV repair had significantly lower in-hospital mortality compared to MV replacement (MVRpr (nZ8, 10.7%), MVRpl (nZ5, 27.8%), PZ0.0027). In Redo/MRC patients, both MV repair and MV replacement had similar mortality (MVRpr (nZ4, 16.0%), MVRpl (nZ1, 12.5%), PZ0.32).
Late survival in Initial patients was not impacted by mitral valve operation. Compared to Initial/MRK patients, Initial/MRC patients with MV repair had similar (PZ0.16) late survivals (Fig. 4) . Though Initial/MRC patients with MV replacement had inferior late survival, statistical significance was not demonstrable due to the small number of late survivors in the subset. In contrast, MV repair (PZ0.014) did not produce equivalent late survival benefit in Redo/MRC patients (Fig. 4) . MV replacement (PZ0.0055) in Redo patients had the worst late survival.
Discussion
Does mitral insufficiency affect survival in CABG patients with ischemic cardiomyopathy? According to Mickleborough and associates [13] who studied 125 initial CABG patients with low ejection fraction (EF!20%), mitral insufficiency did not significantly lower survival. Patients in Mickleborough's series, however, did not have severe mitral regurgitation (4CMR) nor did they have concomitant mitral valve surgery. In our study of ischemic cardiomyopathy patients, we also observed that in the initial CABG patients, significant (3/4C) mitral regurgitation did not have a negative impact on late survival even with the inclusion of patients with severe mitral regurgitation and concomitant mitral valve surgery. In our initial CABG Fig. 3 . Actuarial late survival curves, stratified according to ejection fraction and mitral insufficiency, of ischemic cardiomyopathy patients undergoing Initial or Redo CABG operation. patients, lower ejection fraction, not mitral insufficiency, was an independent predictor of poor late survival. The converse was observed in our redo CABG patients with ischemic cardiomyopathy. Significant (3/4C) mitral regurgitation clearly had a negative impact on both inhospital and subsequent late survival. In this subset, mitral insufficiency and congestive heart failure were the only preoperative variables that were independent predictors of poor late survival in our multivariate analysis. Despite the relatively small number of redo CABG patients with mitral insufficiency, we were still able to demonstrate statistically the negative impact of mitral insufficiency on redo CABG late survival. In contrast, we were unable to demonstrate an independent influence of ejection fraction on late survival (Fig. 3) in the same patient subset. To our knowledge, this prognostic implication of mitral insufficiency in redo CABG had not been previously observed. Several recent studies on redo CABG [8] [9] [10] failed to consider mitral insufficiency as a potential variable with possible detrimental impact on outcome.
It is well known that patients with ischemic cardiomyopathy and mitral insufficiency have lower life expectancy and poorer quality of life. Indeed, in our series, mitral insufficiency was associated preoperatively with increased cardiac and renal co-morbidities in both the initial and the redo CABG patients. Yet mitral insufficiency affected late survival only in the redo CABG patients. Perhaps patients with prior CABG who also had low ejection fraction and mitral insufficiency were simply patients with the most advanced coronary artery disease and the greatest amount of irreversible myocardial damage. Compared to the initial CABG patients, the redo CABG patients probably had much less to benefit from revascularization and mitral valve operation, including mitral valve repair. Moreover, adding mitral valve operation to redo CABG would greatly increase the technical difficulty in these patients, further reducing the benefit-to-risk ratio. The results in our series seemed to support these assumptions. Neither redo CABG nor mitral insufficiency alone significantly altered the late survival (Fig. 2 ). Whereas patients with both redo CABG and mitral insufficiency showed a dramatic decrease in long-term survival.
It was gratifying to observe that mitral insufficiency did not have significant impact on long-term outcome in our initial CABG patients. In fact, patients with better ejection fraction (EFZ26-35%), late survival with and without mitral insufficiency were identical (Fig. 3) . Conceivably, at least in the initial CABG patients, our surgical approach to mitral insufficiency, which included mitral valve repair, had been quite successful in ameliorating the poor late outcome generally associated with mitral insufficiency. Over the study period, our approach to mitral insufficiency in ischemic cardiomyopathy had evolved substantially. With each advancing year, proportionally more mitral valve repairs (nZ99 (55.0%)) were performed in preference to no mitral valve operation (nZ57 (31.7%)) or mitral valve replacement (nZ24 (13.3%)). Majority of the untreated or mitral valve replacement patients were accrued during the earlier years of our experience. Overall, concomitant mitral valve replacement in our series was associated with high postoperative mortality with few late survivors. Mitral valve repair, however, showed a trend towards improved late survival in the initial CABG patients (Fig. 4) . In this subset, concomitant mitral valve repair had yielded very similar late survival as initial CABG returns without mitral insufficiency. Conversely, concomitant mitral valve repair in redo CABG patients did not produce similar late survival benefit. Late survival was significantly worse in redo CABG patients regardless of operative approach to the mitral valve. We therefore, would advocate as other surgeons [14, 15, 16] in employing mitral valve repair, whenever possible, in ischemic cardiomyopathy patients with mitral insufficiency, but would expect much less favorable result in redo CABG patients compared to initial CABG patients.
Results of the present study have influenced our understanding and clinical approach to the surgical management of patients with ischemic cardiomyopathy. Our present surgical treatment has resulted in similar long-term benefit in the initial CABG patients, with or without mitral insufficiency, and the redo CABG patients without mitral insufficiency. Finer risk stratification is required in redo CABG patients with mitral insufficiency. Prior to embarking on high-risk reoperative coronary and mitral operation, this subset of patients would stand to benefit most from having additional viability studies such as PET scanning [1] or cardiac MRI imaging technique [17] . Hausmann and coauthors [18] had described several useful clinical variables that might aid in making the correct decisions in ischemic cardiomyopathy patients. Prior open-heart surgery was one variable to consider when deciding between revascularization versus transplantation. Based on the present series, perhaps only when mitral insufficiency was present in patients with prior CABG should transplantation be seriously offered as an alternative. Certainly, the decision would favor transplantation if such patients also had predominantly heart failure symptoms, relatively poor bypass targets, irreparable mitral valve and extremely low ejection fraction. In our series, late survival was particularly dismal in our redo CABG patients with mitral insufficiency and very low ejection fraction (EF!25%). Their 3-and 5-year late survivals were only 44.4 and 26.8%. Conceivably, novel options including destination therapy with mechanical devices might be explored, since the prognosis with medical treatment of most heart failure patients with cardiomyopathy and mitral insufficiency is dismal.
Study limitations
The present study has limitations similar to other retrospective analyses of a clinical database. Certain important clinical variables were not considered at the inception of the database. All patients had coronary artery disease and had CABG. All patients were presumed to have ischemic cardiomyopathy although some patients might have combined etiologies. In patients with mitral insufficiency, the exact etiology and the exact reason for reoperation were not recorded. The vast majority had ischemic mitral regurgitation and reoperations were performed primarily for ischemic reason rather than valvular disorder. There was considerable variability in the approach to mitral insufficiency and in the mitral valve operation. In the last few years, mitral valve repair has been the preferred treatment in our cardiomyopathy patients with mitral insufficiency. There was much less variability in the conduct of CABG. The majority had at least one arterial revascularization (73.5%). Only saphenous vein grafts were used in the remaining patients due to lack of suitable targets or conduits, or the need to simplify the operation in extraordinarily high risk patients. Myocardial protection consisted of retrograde delivery of cardioplegia in almost all patients (91%). Only recently were off-pump CABG done on these patients. Finally, outcome was all-cause mortality data. The precise causes of death in these patients were not readily available.
Conclusion
Mitral insufficiency had greater survival impact on redo than initial CABG patients with ischemic cardiomyopathy. In redo CABG patients, mitral insufficiency and congestive heart failure were the primary independent predictors of poor late survival. In contrast, ejection fraction and the absence of angina, among other familiar non-cardiac morbidities, were the independent predictors of poor late survival in initial CABG patients. Mitral insufficiency had significantly less impact on initial CABG patients in part due to greater success of mitral valve operation, particularly mitral valve repair, in neutralizing the effect of mitral insufficiency. Unfortunately, mitral valve operation had much less favorable result in redo CABG patients with ischemic cardiomyopathy and mitral insufficiency.
